Buscar
Mostrando ítems 1-5 de 5
Artículo
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
(MDPI AG, 2022)
Abstract: A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced ...
Artículo
Management of NAFLD patients with advanced fibrosis
(Wiley-Blackwell, 2021-06-21)
The prevalence of non alcoholic fatty liver disease (NAFLD) has increased to 25% in the general population and could double by 2030. Liver fibrosis is the main indicator of morbidity and mortality and recent estimations ...
Artículo
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
(OXFORD UNIV PRESS, 2022)
Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi organ involvement. This entity has ...
Artículo
Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
(Frontiers Media, 2021-11-24)
Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has ...
Artículo
Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
(SPRINGER, 2022)
Background NAFLD clinical trials have shown suboptimal results, particularly for liver fibrosis, despite the robust preclinical drug development. We aimed to assess the histological response after the experimental treatment ...